Atazanavir sulphate.

A single centre cohort experience with a new once daily antiretroviral drug. Postgrad Med J (2006) 0.82

Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol (2003) 4.49

Vorinostat. Nat Rev Drug Discov (2007) 2.83

Vascular smooth muscle cells undergo telomere-based senescence in human atherosclerosis: effects of telomerase and oxidative stress. Circ Res (2006) 2.58

Abatacept. Nat Rev Drug Discov (2006) 2.13

Pegloticase. Nat Rev Drug Discov (2011) 1.76

Vemurafenib. Nat Rev Drug Discov (2011) 1.68

Tetrabenazine. Nat Rev Drug Discov (2009) 1.60

Eculizumab. Nat Rev Drug Discov (2007) 1.56

Dabigatran etexilate. Nat Rev Drug Discov (2008) 1.41

Sipuleucel-T. Nat Rev Drug Discov (2010) 1.37

Tocilizumab. Nat Rev Drug Discov (2009) 1.36

Effect of decompressive craniectomy on intracranial pressure and cerebrospinal compensation following traumatic brain injury. J Neurosurg (2008) 1.35

Cabazitaxel. Nat Rev Drug Discov (2010) 1.34

Denosumab. Nat Rev Drug Discov (2010) 1.31

Cetuximab. Nat Rev Drug Discov (2004) 1.31

Panitumumab. Nat Rev Drug Discov (2006) 1.31

Everolimus. Nat Rev Drug Discov (2009) 1.29

Liraglutide. Nat Rev Drug Discov (2010) 1.27

Dasatinib. Nat Rev Drug Discov (2006) 1.25

Azacitidine. Nat Rev Drug Discov (2005) 1.23

Enfuvirtide. Nat Rev Drug Discov (2003) 1.22

Daptomycin. Nat Rev Drug Discov (2003) 1.22

Erlotinib hydrochloride. Nat Rev Drug Discov (2005) 1.22

Asenapine. Nat Rev Drug Discov (2009) 1.21

Ipilimumab. Nat Rev Drug Discov (2011) 1.20

Duloxetine hydrochloride. Nat Rev Drug Discov (2004) 1.17

Vismodegib. Nat Rev Drug Discov (2012) 1.16

Eribulin mesylate. Nat Rev Drug Discov (2011) 1.14

Oxaliplatin. Nat Rev Drug Discov (2004) 1.14

Tolvaptan. Nat Rev Drug Discov (2009) 1.13

Febuxostat. Nat Rev Drug Discov (2009) 1.12

Ivacaftor. Nat Rev Drug Discov (2012) 1.12

Golimumab. Nat Rev Drug Discov (2009) 1.11

Lapatinib. Nat Rev Drug Discov (2007) 1.10

Lacosamide. Nat Rev Drug Discov (2008) 1.09

Bevacizumab. Nat Rev Drug Discov (2004) 1.09

Ranibizumab. Nat Rev Drug Discov (2006) 1.08

Sunitinib maleate. Nat Rev Drug Discov (2006) 1.07

Crizotinib. Nat Rev Drug Discov (2011) 1.05

Plerixafor. Nat Rev Drug Discov (2009) 1.04

Brentuximab vedotin. Nat Rev Drug Discov (2012) 1.04

Aflibercept. Nat Rev Drug Discov (2012) 1.04

Exenatide. Nat Rev Drug Discov (2005) 1.02

Pazopanib. Nat Rev Drug Discov (2010) 1.02

Decitabine. Nat Rev Drug Discov (2006) 1.02

Ustekinumab. Nat Rev Drug Discov (2009) 1.02

Varenicline. Nat Rev Drug Discov (2006) 0.99

Gefitinib. Nat Rev Drug Discov (2003) 0.99

Pregabalin. Nat Rev Drug Discov (2005) 0.98

Certolizumab pegol. Nat Rev Drug Discov (2008) 0.98

Teriparatide. Nat Rev Drug Discov (2003) 0.98

Belatacept. Nat Rev Drug Discov (2011) 0.96

Ruxolitinib. Nat Rev Drug Discov (2012) 0.96

Telavancin. Nat Rev Drug Discov (2009) 0.94

Dronedarone. Nat Rev Drug Discov (2009) 0.93

Ezogabine (retigabine). Nat Rev Drug Discov (2011) 0.92

Ecallantide. Nat Rev Drug Discov (2010) 0.91

Posaconazole. Nat Rev Drug Discov (2007) 0.91

Tafamidis. Nat Rev Drug Discov (2012) 0.91

Tigecycline. Nat Rev Drug Discov (2005) 0.91

Surgery for brain edema. Neurosurg Focus (2007) 0.91

Pegaptanib sodium. Nat Rev Drug Discov (2005) 0.90

Prasugrel. Nat Rev Drug Discov (2009) 0.90

Memantine hydrochloride. Nat Rev Drug Discov (2004) 0.88

Telbivudine. Nat Rev Drug Discov (2007) 0.87

Fresh from the pipeline. Ticagrelor. Nat Rev Drug Discov (2011) 0.87

Romiplostim. Nat Rev Drug Discov (2008) 0.86

Sitagliptin. Nat Rev Drug Discov (2007) 0.86

Alvimopan. Nat Rev Drug Discov (2008) 0.86

Tipranavir. Nat Rev Drug Discov (2005) 0.85

Roflumilast. Nat Rev Drug Discov (2010) 0.85

Specificity concerns with antibodies for receptor mapping. Nat Rev Drug Discov (2009) 0.85

Quadrivalent human papillomavirus recombinant vaccine. Nat Rev Drug Discov (2006) 0.85

Velaglucerase alfa. Nat Rev Drug Discov (2010) 0.85

Aripiprazole. Nat Rev Drug Discov (2003) 0.84

Differential cyclin E expression in human in-stent stenosis smooth muscle cells identifies targets for selective anti-restenosis therapy. Cardiovasc Res (2003) 0.83

Pemetrexed disodium. Nat Rev Drug Discov (2004) 0.83

Belimumab. Nat Rev Drug Discov (2011) 0.83

Pirfenidone. Nat Rev Drug Discov (2011) 0.83

Pasireotide. Nat Rev Drug Discov (2012) 0.81

Ranolazine. Nat Rev Drug Discov (2006) 0.81

Inhaled aztreonam. Nat Rev Drug Discov (2010) 0.81

Efalizumab. Nat Rev Drug Discov (2004) 0.81

Entecavir. Nat Rev Drug Discov (2005) 0.81

Ofatumumab. Nat Rev Drug Discov (2010) 0.81

Eplerenone. Nat Rev Drug Discov (2003) 0.80

Abiraterone acetate. Nat Rev Drug Discov (2011) 0.80

Natalizumab. Nat Rev Drug Discov (2005) 0.80

Meningococcal group A, C, Y and W-135 conjugate vaccine. Nat Rev Drug Discov (2010) 0.80

Fresh from the pipeline: Ramelteon. Nat Rev Drug Discov (2005) 0.79

Bendamustine. Nat Rev Drug Discov (2008) 0.79

Galsulfase. Nat Rev Drug Discov (2006) 0.78

Rasagiline. Nat Rev Drug Discov (2005) 0.78

Lisdexamfetamine dimesylate. Nat Rev Drug Discov (2007) 0.78

Omalizumab. Nat Rev Drug Discov (2004) 0.78

Clofarabine. Nat Rev Drug Discov (2005) 0.78

Telithromycin. Nat Rev Drug Discov (2004) 0.77